Vera Therapeutics

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

BRISBANE, Calif., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced new clinical data presented on the Company's two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022 in Orlando, Florida.

Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney W

BRISBANE, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced two new abstracts featuring new clinical data on the Company's two product candidates, MAU868 in kidney transplant and atacicept in immunoglobulin A nephropathy (IgAN). These data are to be presented in oral and poster sessions, respectively, at the American Society of Nephrology Kidney Week 2022 Annual Meeting, being held November 3-6, 2022 in Orlando, Florida. The oral presentation on MAU868 includes final results from the Phase 2 clinical trial of MAU868 versus placebo to treat BKV in kidney transplant patients. The poster presentation on atacicept includes a new analysis of previously presented clinical data from the Phase 2a JANUS clinical trial evaluating atacicept in patients with IgAN.

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202

The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to a 63.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following conferences in September, as detailed below:

Vera Therapeutics to Present at Upcoming Conferences in September 2022

The consensus price target hints at a 76.2% upside potential for Vera Therapeutics, Inc. (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High?

The consensus price target hints at a 78.8% upside potential for Vera Therapeutics, Inc. (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect?

BRISBANE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the quarter ended June 30, 2022.

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 13th Annual Wedbush PacGrow Healthcare Conference, which is taking place virtually August 9-10, 2022. The Company will also participate in one-on-one investor meetings.

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Topline results anticipated fourth quarter of 2022 Topline results anticipated fourth quarter of 2022

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

BRISBANE, Calif., June 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients showed that MAU868 was well tolerated and demonstrated significant BK antiviral activity in kidney transplant recipients with BK viremia. These data were delivered today as a late-breaking oral presentation by Daniel C. Brennan, M.D., medical director, Comprehensive Transplant Center, professor of medicine, The Johns Hopkins University School of Medicine, and study investigator, at the American Transplant Congress (ATC) 2022 in Boston, Massachusetts.

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 2022 Jefferies Healthcare Conference, being held June 8-10, 2022 in New York, NY. The management team will also participate in one-on-one investor meetings.

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced new clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS trial in patients with IgA nephropathy (IgAN) and first-time results from a post-hoc analysis of the Phase 2 APRIL-SLE study in patients with systemic lupus erythematosus (SLE). These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

BRISBANE, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the quarter ended March 31, 2022.

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following conferences in May, as detailed below:

Vera Therapeutics to Present at Upcoming Conferences in May 2022

BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced two oral presentations featuring new clinical data on the Company's lead product candidate, atacicept, to be presented at the 59th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually, at the Paris Expo Porte de Versailles. The oral presentations include new clinical data from the Phase 2a JANUS clinical trial of atacicept in patients with IgA nephropathy (IgAN) and first-time renal data from a post-hoc analysis of the Phase 2 APRIL-SLE study evaluating atacicept in patients with systemic lupus erythematosus (SLE).

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients will be delivered in a late-breaking oral presentation at the American Transplant Congress (ATC) 2022 in Boston, Massachusetts.

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey has served as president and chief executive officer (CEO) of Exelixis, Inc. since July 2010.

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D.

BRISBANE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the fourth quarter and full year ended December 31, 2021.

Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients

Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D.

BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022.

Vera Therapeutics to Host Business Update Call

BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder and CEO, will present and participate in one-on-one investor meetings at the 42nd Annual Cowen Health Care Conference taking place March 7-9, 2022.

Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference

BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its public offering of 5,742,026 shares of its Class A common stock at a price to the public of $15.00 per share, which includes the full exercise of the underwriters' option to purchase up to 748,959 additional shares. The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $86.1 million. All of the shares were sold by Vera.

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Results from the phase 2 study using MAU868 for the treatment of patients with the BK virus are expected by mid-2022. Results from the phase 2b ORIGIN study using atacicept for the treatment of patients with IgA Nephropathy are expected by Q4 of 2022.

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN - - Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder and CEO, will present and participate in one-on-one investor meetings at the 40th Annual J.P. Morgan Healthcare Conference taking place virtually January 10-13, 2022.

News for Vera Therapeutics Stock (VERA)